Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50bn

Eli Lilly and Company has announced plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical manufacturing sites in the United States, bringing the company’s total U.S. capital expansion commitments to more than $50bn since 2020. Three of the future U.S. sites announced will focus on manufacturing active pharmaceutical ingredients…